Printer Friendly
The Free Library
14,800,529 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Alnylam Added to NASDAQ Biotechnology Index.


CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals Alnylam Pharmaceuticals Inc. (NYSE: ALNY), a biopharmaceutical company, engages in the development and commercialization of therapeutic products based on RNA interference (RNAi) in the United States. , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it will be added to the NASDAQ Biotechnology Index The NASDAQ Biotechnology Index includes securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria.  (Nasdaq: NBI NBI Niels Bohr Institute (Denmark)
NBI National Bureau of Investigation
NBI Nile Basin Initiative (Uganda)
NBI National Bridge Inventory
NBI Nation Brands Index (statistics) 
), effective with the U.S. market open on Monday, November 14, 2005.

"We are proud to be selected to join the NASDAQ Biotechnology Index," said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam Pharmaceuticals. "We believe our inclusion in this index reflects the increased awareness in the investment community of the potential of RNAi for therapeutic applications, and the importance of translating this breakthrough in biology into innovative medicines."

The NASDAQ Biotechnology Index was launched in 1993 and includes biotechnology and pharmaceutical companies listed on the NASDAQ National Market that meet minimum requirements for market value, average daily share volume and seasoning as a public company. The NASDAQ Biotechnology Index is ranked on a semi-annual basis in May and November and serves as the basis for the iShares NASDAQ Biotechnology Index Fund(SM) (AMEX AMEX

See: American Stock Exchange
:IBB IBB International Broadcasting Bureau (US government)
IBB Institute of Biochemistry and Biophysics
IBB Islamic Bank of Britain
IBB I'll Be Back
IBB Intentional Base on Balls
). For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit www.nasdaq.com.

About Alnylam

Alnylam is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference RNA interference
n.
A process in which the introduction of double-stranded RNA into a cell inhibits the expression of genes.
, or RNAi. The company, founded in 2002 by scientific pioneers in the field of RNAi, maintains a leadership position in fundamental patents, technology, and know-how relating to RNAi. Alnylam is applying its expertise in RNAi to address multiple therapeutic opportunities that cannot effectively be addressed with small molecules or antibodies, the two current major classes of drugs. The company's expertise in designing and optimizing RNAi therapeutics has enabled Alnylam to form major alliances with leading companies including Merck, Medtronic, and Novartis. The company's global headquarters are in Cambridge, Massachusetts, with an additional operating unit operating unit

A type of operating company that engages in transactions with outsiders and that is owned by another business. For example, in 1995 the stockholders of Capital Cities/ABC approved a $19 billion merger with the Walt Disney Company, whereupon
 in Kulmbach, Germany. For more information, please visit www.alnylam.com.

Alnylam Forward-Looking Statements

Various statements in this release concerning our future expectations, plans and prospects, such as the company's inclusion in the NASDAQ Biotechnology Index, constitute forward-looking statements for the purposes of the safe harbor Safe Harbor

1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated.

2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive.
 provisions under The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our approach to discover and develop novel drugs, which is unproven and may never lead to marketable products; our ability to obtain additional funding to support our business activities; our dependence on third parties for development, manufacture, marketing, sales and distribution of our products; the successful development of products, all of which are in early stages of development; obtaining regulatory approval for products; competition from others using technology similar to ours and others developing products for similar uses; obtaining, maintaining and protecting intellectual property utilized by our products; our dependence on collaborators; and our short operating history; as well as those risks more fully discussed in the "Certain Factors That May Affect Future Results" section of our most recent quarterly report on Form 10-Q Form 10-Q

See 10-Q.
 on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We do not assume any obligation to update any forward-looking statements.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Nov 14, 2005
Words:542
Previous Article:Excelligence Learning Corporation Announces Delay in Filing of Form 10-Q and Request for Further Filing Extension From Nasdaq.
Next Article:Admiral Bay Welcomes Thomas R. Tough To The Board.
Topics:



Related Articles
Alnylam to Webcast Presentation at the Annual BIO Investor Forum on October 19, 2005.
Alnylam to Webcast Presentation at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on November 8, 2005.
Panacos Added to NASDAQ Biotechnology Index.
Alnylam to Webcast its R&D Day on Wednesday, December 14, 2005.
Alnylam Announces Pandemic Flu as Next Development Program; Obtains Initial Federal Funding to Develop RNAi Therapeutics for Pandemic Influenza and...
Novartis and Alnylam Announce New Collaboration to Develop RNAi Therapeutics for Pandemic Flu.
Novartis and Alnylam Announce New Collaboration to Develop RNAi Therapeutics for Pandemic Flu.
Alnylam to Host Conference Call to Discuss Collaboration with Novartis to Develop RNAi Therapeutics for Pandemic Flu.
Alnylam to Webcast Presentation at the Bear Stearns Biotech Boston Confab.
OMRIX Biopharmaceuticals To Join NASDAQ Biotechnology Index(R).

Terms of use | Copyright © 2010 Farlex, Inc. | Feedback | For webmasters | Submit articles